Robert Haile to Heterozygote
This is a "connection" page, showing publications Robert Haile has written about Heterozygote.
Connection Strength
1.040
-
Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome. J Natl Cancer Inst. 2015 Sep; 107(9).
Score: 0.118
-
Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst. 2013 Feb 20; 105(4):274-9.
Score: 0.100
-
Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst. 2012 Sep 19; 104(18):1363-72.
Score: 0.097
-
Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. Int J Cancer. 2011 Nov 01; 129(9):2256-62.
Score: 0.088
-
Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst. 2010 Feb 03; 102(3):193-201.
Score: 0.080
-
BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev. 2006 Oct; 15(10):1863-70.
Score: 0.064
-
Breast cancer risks for BRCA1/2 carriers. Science. 2004 Dec 24; 306(5705):2187-91; author reply 2187-91.
Score: 0.057
-
Risk-reducing hysterectomy and bilateral salpingo-oophorectomy in female heterozygotes of pathogenic mismatch repair variants: a Prospective Lynch Syndrome Database report. Genet Med. 2021 04; 23(4):705-712.
Score: 0.043
-
Cancer Risks for PMS2-Associated Lynch Syndrome. J Clin Oncol. 2018 10 10; 36(29):2961-2968.
Score: 0.037
-
Multivitamin, calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome. Int J Epidemiol. 2016 06; 45(3):940-53.
Score: 0.031
-
Does risk of endometrial cancer for women without a germline mutation in a DNA mismatch repair gene depend on family history of endometrial cancer or colorectal cancer? Gynecol Oncol. 2014 May; 133(2):287-92.
Score: 0.027
-
Risk of colorectal cancer for carriers of mutations in MUTYH, with and without a family history of cancer. Gastroenterology. 2014 May; 146(5):1208-11.e1-5.
Score: 0.027
-
Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report. Eur J Cancer. 2013 Sep; 49(14):2979-85.
Score: 0.025
-
Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat. 2013 Mar; 34(3):490-7.
Score: 0.025
-
Are the common genetic variants associated with colorectal cancer risk for DNA mismatch repair gene mutation carriers? Eur J Cancer. 2013 May; 49(7):1578-87.
Score: 0.025
-
Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol. 2013 Feb 01; 31(4):433-9.
Score: 0.025
-
Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol. 2012 Mar 20; 30(9):958-64.
Score: 0.023
-
Variants in activators and downstream targets of ATM, radiation exposure, and contralateral breast cancer risk in the WECARE study. Hum Mutat. 2012 Jan; 33(1):158-64.
Score: 0.023
-
Body mass index in early adulthood and endometrial cancer risk for mismatch repair gene mutation carriers. Obstet Gynecol. 2011 Apr; 117(4):899-905.
Score: 0.022
-
Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut. 2011 Jul; 60(7):950-7.
Score: 0.022
-
Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study. Breast Cancer Res Treat. 2010 Feb; 120(1):175-83.
Score: 0.019
-
Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology. 2009 Apr; 136(4):1251-60.
Score: 0.019
-
Variation of breast cancer risk among BRCA1/2 carriers. JAMA. 2008 Jan 09; 299(2):194-201.
Score: 0.018
-
Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA. 2005 Apr 27; 293(16):1979-85.
Score: 0.015
-
Designing and implementing quality control for multi-center screening of mutations in the ATM gene among women with breast cancer. Hum Mutat. 2003 May; 21(5):542-50.
Score: 0.013